French, J A
"Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs"
Epilepsia 1996 ; 37 Suppl 2():S23-S26
- A number of new antiepileptic drugs (AEDs), including topiramate (TPM), felbamate (FBM), and gabapentin (GBP), are approved or believed to be close to approval for marketing in the United States. Key efficacy findings for these AEDs in refractory partial epilepsy were reviewed. Large and significant drug-placebo differences were observed with TPM in two large dose-finding trials conducted in the United States. The minimal effective dose of TPM in the population studied was determined to be approximately 200 mg/day, and doses above 600 mg/day produced good efficacy but little incremental benefit versus the lower dosages for the overall study population. FBM is active in partial epilepsy, although seizure reduction is less marked and drug interactions complicate the findings. GBP is also active in this population, but only the 1,800 mg/day dosage was significantly better than placebo with respect to percent responders. It may be useful to explore higher dosage ranges for both FBM and GBP if they can be well tolerated
Check for full text:
# 102119 (MEDL:8641243)
This publication list a product of the NYU Faculty Bibliography.